https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/aclaris-therapeutics-partners-cipher-pharmaceuticals-seek-regulatory-approval-commercialize-101-40-topical-solution/
Aclaris Therapeutics (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative...
aclaris therapeuticsregulatory approvalpartnerscipherpharmaceuticals
https://www.nasdaq.com/market-activity/stocks/acrs/press-releases
Get the latest insights on Aclaris Therapeutics, Inc. Common Stock (ACRS) with press releases and corporate news to help you in your trading and investing...
aclaris therapeuticscommon stockpress releasesincacrs
https://www.biospace.com/aclaris-therapeutics-to-participate-in-the-jefferies-healthcare-conference-june-01-2022
Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare...
aclaris therapeuticshealthcare conferenceparticipatejefferiesjune
https://www.nasdaq.com/market-activity/stocks/acrs/historical
Find the latest historical data for Aclaris Therapeutics, Inc. Common Stock (ACRS) at Nasdaq.com. View historical data in a monthly, bi-annual, or yearly...
aclaris therapeuticscommon stockhistorical dataincacrs
https://fprimecapital.com/company/aclaris-therapeutics/
Jun 3, 2025 - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative...
aclaris therapeuticsfprimecapital